€1.823 billion revenue (FY 2018) (approximately 234.0 billion yen)

92.3% of revenue from prescription ophthalmic pharmaceuticals

Overseas sales accounts for 31.5% of corporate revenue (FY 2018)

#1 in Japanese prescription ophthalmic pharmaceuticals

Over 4,070+ employees globally

Dedicated facilities for ongoing research and development: Nara Research and Development Centre (Japan), Evry (France), Emeryville, Miami and Goleta (US)

Products supplied in over 60 countries

Six manufacturing sites: Noto and Shiga (Japan), Suzhou (China), Tampere (Finland), Miami and Goleta (US)